Light-activated AU-011
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Trial Timeline
Feb 27, 2017 → Jan 26, 2021
NCT ID
NCT03052127About Light-activated AU-011
Light-activated AU-011 is a phase 1/2 stage product being developed by Aura Biosciences for Uveal Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03052127. Target conditions include Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03052127 | Phase 1/2 | Completed |
Competing Products
20 competing products in Uveal Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Selumetinib, 100mg + Selumetinib, 125mg + Selumetinib, 150mg + Selumetinib, 175mg + Selumetinib, 200mg + Selumetinib, 225mg | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab + Entinostat | Merck | Phase 2 | 52 |
| Pembrolizumab + Olaparib | Merck | Phase 2 | 52 |
| Pembrolizumab 25 MG/1 ML Intravenous Solution | Merck | Phase 2 | 52 |
| AEB071 | Novartis | Phase 1 | 33 |
| LXS196 + LXS196 and HDM201 | Novartis | Phase 1 | 33 |
| DYP688 | Novartis | Phase 1/2 | 41 |
| RAD001 (Everolimus) and Pasireotide (SOM230) LAR | Novartis | Phase 2 | 52 |
| ranibizumab + triamcinolone acetonide | Novartis | Phase 2/3 | 65 |
| Crizotinib | Pfizer | Phase 2 | 51 |
| Dacarbazine + Sunitinib | Pfizer | Phase 2 | 51 |
| AEB071 + MEK162 | Pfizer | Phase 1/2 | 40 |
| Binimetinib + Belinostat | Pfizer | Phase 2 | 51 |
| Ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| ipilimumab + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| ZIV-Aflibercept + Cemiplimab | Sanofi | Phase 2 | 51 |
| Ziv-Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |
| XmAb®23104 + Yervoy® (ipilimumab) | ICON plc. | Phase 1 | 30 |